Mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome, is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GUSB gene. The deficiency of the enzyme beta-glucuronidase prevents the correct degradation of certain glycosaminoglycans, which progressively accumulate in cells and cause multisystem involvement, especially bone, visceral, and, in some cases, neurological.
Mucopolysaccharidosis type 7
The GUSB gene encodes the enzyme beta-glucuronidase, located in lysosomes, where it participates in the degradation of glycosaminoglycans (GAGs) such as dermatan sulfate, heparan sulfate, and chondroitin sulfate. These compounds are part of the extracellular matrix and connective tissues; therefore, their proper degradation and recycling are essential for maintaining the normal function of multiple organs.
When GUSB presents biallelic pathogenic variants, beta-glucuronidase activity is markedly reduced or absent. As a consequence, partially degraded GAGs accumulate within lysosomes and cause progressive cellular damage. MPS VII shows great clinical variability, from severe prenatal or neonatal forms with non-immune fetal hydrops to attenuated forms with infantile, juvenile, or adult onset. Inheritance is autosomal recessive: an affected person inherits an altered copy of the gene from each parent. It is an ultrarare disease, with an estimated global incidence of less than 1 in 250,000 live births, although specific population clusters have been described.
Symptoms
The clinical presentation is highly variable. The most severe forms can manifest before birth or at birth with fetal hydrops, cholestatic jaundice, hepato-splenomegaly, and respiratory distress. In infancy, coarse facial features, disproportionate short stature, multiple dysostoses, joint stiffness, hernias, corneal opacities, hearing loss, valvular heart disease, and respiratory disease may appear. Neurological development can be affected to a variable degree, ranging from mild delay to moderate or severe intellectual disability. Attenuated forms usually progress more slowly and may present with skeletal or joint manifestations.
Disease management
The management of MPS VII requires follow-up in centers with experience in lysosomal diseases and a multidisciplinary approach. Enzyme replacement therapy with vestronidase alfa is the available disease-modifying treatment and is administered intravenously every two weeks; it can reduce urinary GAG levels and improve some systemic manifestations, although it is not expected to significantly correct central nervous system involvement. Treatment is complemented by orthopedic, respiratory, cardiac, auditory, and ophthalmologic monitoring, rehabilitation, airway management, and treatment of complications such as cervical instability, spinal stenosis, hernias, or feeding problems. Hematopoietic stem cell transplantation has been used in selected cases, with variable results.
Genes analyzed
Bibliography
Sun A, Wang R. Mucopolysaccharidosis Type VII. 2024 Jan 4. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Chandler NJ, Ramachandran V, Beesley C, et al. Prenatal diagnosis of mucopolysaccharidosis type VII facilitating treatment in neonatal period. Prenat Diagn. 2023 Nov;43(12):1567-1569.
Grant CL, López-Valdez J, Marsden D, et al. Mucopolysaccharidosis type VII (Sly syndrome) - What do we know? Mol Genet Metab. 2024 Mar;141(3):108145.
